NCT01888081View on ClinicalTrials.gov

A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2020

Conditions
Melanoma
Interventions
DRUG

A-dmDT390-bisFv(UCHT1) (Resimmune®)

RADIATION

Ionizing Radiation

Trial Locations (1)

40202

James Graham Brown Cancer Center, Louisville

Sponsors

Lead Sponsor

Angimmune LLC
All Listed Sponsors
collaborator

University of Louisville

OTHER

lead

Angimmune LLC

INDUSTRY

NCT01888081 - A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | Biotech Hunter | Biotech Hunter